- Home
- MRK vs CCIA Comparison
MRK vs CCIA Comparison
Compare MRK & CCIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRK
- CCIA
- Stock Information
- Founded
- MRK 2000
- CCIA N/A
- Country
- MRK United States
- CCIA
- Employees
- MRK N/A
- CCIA N/A
- Industry
- MRK Biotechnology: Pharmaceutical Preparations
- CCIA
- Sector
- MRK Health Care
- CCIA
- Exchange
- MRK Nasdaq
- CCIA Nasdaq
- Market Cap
- MRK 218.8B
- CCIA N/A
- IPO Year
- MRK N/A
- CCIA 2023
- Fundamental
- Price
- MRK $87.26
- CCIA $24.98
- Analyst Decision
- MRK Buy
- CCIA
- Analyst Count
- MRK 15
- CCIA 0
- Target Price
- MRK $105.14
- CCIA N/A
- AVG Volume (30 Days)
- MRK 13.0M
- CCIA N/A
- Earning Date
- MRK 10-30-2025
- CCIA N/A
- Dividend Yield
- MRK 3.82%
- CCIA N/A
- EPS Growth
- MRK 20.41
- CCIA N/A
- EPS
- MRK 6.49
- CCIA N/A
- Revenue
- MRK $63,616,000,000.00
- CCIA N/A
- Revenue This Year
- MRK $1.84
- CCIA N/A
- Revenue Next Year
- MRK $5.24
- CCIA N/A
- P/E Ratio
- MRK $13.07
- CCIA N/A
- Revenue Growth
- MRK 1.82
- CCIA N/A
- 52 Week Low
- MRK $73.31
- CCIA N/A
- 52 Week High
- MRK $110.19
- CCIA N/A
- Technical
- Relative Strength Index (RSI)
- MRK 58.61
- CCIA 30.24
- Support Level
- MRK $83.16
- CCIA $25.10
- Resistance Level
- MRK $85.50
- CCIA $25.25
- Average True Range (ATR)
- MRK 1.76
- CCIA 0.07
- MACD
- MRK -0.03
- CCIA -0.01
- Stochastic Oscillator
- MRK 52.21
- CCIA 3.53
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
About CCIA Carlyle Credit Income Fund 8.75% Series A Preferred Shares due 2028
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.